Abstract Objective Invasive fungal infection is a major cause of morbidity and mortality in patients with
Introduction

Invasive fungal infection (IFI) is a major cause of morbidity and mortality in patients with prolonged neutropenia after intensive chemotherapy. Difficulty in early diagnosis causes a treatment delay, which makes the prognosis extremely poor. These situations have led to the empirical use of antifungal agents in febrile neutropenic patients unresponsive to broad-spectrum antibacterial treatment (1-14). For this indication, amphotericin B (AMPH-B) has been the
F i g u r e 1 . De s i g n o f t h e S t u d y . P a t i e n t s d e v e l o p i n g f e b r i l e n e u t r o p e n i a r e c e i v e d a n t i b a c t e r i a l t r e a t me n t i mme d i a t e l y a ft e r e n r o l l me n t . Mi c a f u n g i n wa s a d d e d f o r t h o s e r e ma i n i n g n e u t r o p e n i c a n d h a v i n g p e r s i s t e n t o r r e c u r r e n t f e v e r a f t e r a t l e a s t 5 d a y s o f a n t i b a c t e r i a l t h e r a p y , a n d a l s o f o r t h o s e wh o s e b l o o d c u l t u r e s we r e p o s i t i v e f o r f u n g i o r t h o s e wh o h a d a n e l e v a t i o n o f s e r u m β -D-g l u c a n b e f o r e d a y 5 .
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This was a prospective non-randomized study conducted in a single center. T a b l e 2 . De t a i l s o f P a t i e n t s Re c e i v i n g E mp i r i c a l Mi c a f u n g i n T a b l e 3 . T r e a t me n t S c h e d u l e s a n d (4, 5, 7, 8, 13) . But its routine use is limited due to high acquisition cost. The azole antifungal agents are considered to be less toxic than AMPH-B, and several studies showed that FLCZ or itraconazole (ITCZ) were equally effective as compared to 6, 9, 10) . Nevertheless, one of the major concerns about the use of FLCZ is ascribed to its lack of activity against Aspergillus species and some non-albicans Candida species, i.e., C. krusei and C. glabrata. An increasing prevalence of such resistant strains has been reported, primarily due to the widespread use of prophylactic ITCZ, voriconazole and caspofungin (10, 11, 14) .
MCFG, similar to caspofungin, is an echinocandin agent, which targets the fungal cell walls. The in vitro and in vivo studies have shown that it has a broad spectrum and strong activity with fewer adverse effects (15) (16) (17) (18) (3, 6, 7, 9, 10, 13 
